Neovacs Acquires Interferon Alpha Manufacturing Technology
Neovacs acquired Amegabiotech’s Interferon Alpha manufacturing license for the manufacture of its lead therapeutic candidate.
On Nov. 15, 2016 Neovacs announced an agreement with the Argentinean company Amegabiotech to acquire its Interferon Alpha (IFNα) manufacturing license. IFNα is a key component of Neovacs’ lead therapeutic candidate, IFNα Kinoid, which is composed of inactivated IFNα coupled with a carrier protein, keyhole limpet hemocyanin. According to Neovacs, the acquisition significantly strengthens the company’s commercialization strategy of the IFNα Kinoid therapeutic vaccine for lupus.
Amegabiotech is a producer of IFNα protein and a long-term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNα Kinoid in lupus. Their product is recognized by the international biotechnology and pharmaceutical industry for the quality of its technological manufacturing, which also meets all relevant international GMP standards.
Source: Neovacs
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
